跳至主要内容
临床试验/NCT06429748
NCT06429748进行中(未招募)不适用

A Prospective Study to Evaluate Symptoms Following Repetitive Transcranial Magnetic Stimulation (rTMS)

Neuronetics2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年5月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Neuronetics
入组人数
20
试验地点
2
主要终点
Changes in multiple symptoms after rTMS treatment.

研究概览

简要总结

A prospective study to evaluate symptoms following repetitive transcranial Magnetic stimulation.

详细描述

Open-label, multicenter, prospective pilot study conducted in an adult population receiving rTMS treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults, 22 to 70 years of age
  • Voluntarily provides written informed consent and agree to comply with study procedures, including attending all study visits and completing all study assessments.
  • Score > or = 8 on ISI scale
  • If subject is on any psychiatric or sleep medication, dose must be stable for two weeks prior to enrollment and remain stable throughout the trial.
  • If female, not breastfeeding, no known or suspected pregnancy, a status of nonchildbearing potential or use of an acceptable form of birth control.
  • Subject on stable dose regime for other concurrent medications like hormonal therapy for menopause transition etc.

排除标准

  • Subject meets any one or more of the contraindications for TMS Therapy per current treatment guidelines as determined by the PI.
  • History of head trauma associated with loss of consciousness or diagnosed as concussion.
  • History of fainting, syncope, hearing problems or ringing in the ears (tinnitus)
  • Has any metallic implant(s) in or near the head (e.g., pacemaker, defibrillator, neurostimulator, etc.) including any splinters, fragments, clips, etc.
  • Has an implanted stimulator device (including device leads) in or near the head. (e.g. deep brain stimulator, cochlear implant, vagus nerve stimulator.)
  • Has medication infusion device.
  • Subjects with any prior TMS or MRI complications, or any other issues/circumstance which, in the opinion of the investigator, might interfere with safety, study participation, or which might confound data interpretation.
  • PHQ-9 total score > or = 10 or QIDS total score > or =
  • Drug abuse or dependence of the illicit substance. (Abuse or Dependence, as defined by DSM-V-TR)
  • Current diagnosis or known history of neurologic disease (e.g., epilepsy, convulsion, seizure)
  • Other known disorder (e.g., narcolepsy, a breathing-related sleep disorder like Obstructive Sleep Apnea, a circadian rhythm sleep-wake disorder, a parasomnia) as defined by DSM-V-TR.
  • Has a clinically significant abnormality on the screening examination.
  • Participation in any clinical trial with an investigational drug or device within the past month or concurrent with study participation.

研究组 & 干预措施

Open Label

Experimental

Single Group

干预措施: rTMS (Device)

结局指标

主要结局

Changes in multiple symptoms after rTMS treatment.

时间窗: 4 weeks

Assess changes in multiple symptoms scores based on patient reported questionnaires from baseline to end of acute.

次要结局

  • Durability of changes in symptoms(16 weeks)

研究者

发起方
Neuronetics
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验